REVB — Revelation Biosciences Share Price
0.000.00%
Last trade - 00:00- $3.12m
- -$11.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.36 | ||
| Price to Tang. Book | 0.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.36% | ||
| Return on Equity | -91.95% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 20th, 2019
- Public Since
- October 8th, 2020
- No. of Shareholders
- 66
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,632,935
- Address
- 4660 Lajolla Village Drive, Suite 100, SAN DIEGO, 92122
- Web
- https://www.revbiosciences.com/
- Phone
- +1 6508003717
- Auditors
- BAKER TILLY US LLP
Upcoming Events for REVB
Q2 2024 Revelation Biosciences Inc Earnings Release
Q3 2024 Revelation Biosciences Inc Earnings Release
Similar to REVB
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Revelation Biosciences share price?
As of Today at 22:57 UTC, shares in Revelation Biosciences are trading at $2.11. This share price information is delayed by 15 minutes.
How has the Revelation Biosciences share price performed this year?
Shares in Revelation Biosciences last closed at $2.11 and the price had moved by -93.24% over the past 365 days. In terms of relative price strength the Revelation Biosciences share price has underperformed the S&P500 Index by -94.62% over the past year.
What are the analyst and broker recommendations for Revelation Biosciences?
The overall consensus recommendation for Revelation Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Revelation Biosciences dividend yield?
Revelation Biosciences does not currently pay a dividend.
Does Revelation Biosciences pay a dividend?
Revelation Biosciences does not currently pay a dividend.
When does Revelation Biosciences next pay dividends?
Revelation Biosciences does not currently pay a dividend.
How do I buy Revelation Biosciences shares?
To buy shares in Revelation Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Revelation Biosciences?
As of the previous close price of $2.11, shares in Revelation Biosciences had a market capitalisation of $3.45m.
Where are Revelation Biosciences shares listed?
Here are the trading details for Revelation Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: REVB
What kind of share is Revelation Biosciences?
Based on an overall assessment of its quality, value and momentum Revelation Biosciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Revelation Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Revelation Biosciences is $18.70. That is 786.26% above the last closing price of $2.11.
Analysts covering Revelation Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$7.54 for the next financial year.
What is the trend in the Revelation Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Revelation Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -88.49%.
As of the last closing price of $2.11, shares in Revelation Biosciences were trading -79.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Revelation Biosciences PE Ratio?
The Revelation Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Revelation Biosciences?
We do not have data on Revelation Biosciences' directors